10月8日，金斯瑞生物科技盘中下跌3.22%，报41.44港元，成交额7839.2万港元。此前一日该股已大跌12.70%，今日延续弱势，反映医药板块整体回调压力。
消息面上，隔夜美股医药板块暴跌，艾力斯医药宣布伏美替尼全球三期失利后股价重挫46.98%，拖累港股医药及生物科技板块情绪。此外，花旗近期将Moderna评级从“中性”下调至“卖出”，目标价由80美元大幅下调至60美元，加剧市场对创新药及CXO板块估值担忧。
金斯瑞生物科技自7月初至10月6日累计涨幅一度接近270%，短期获利盘积累较多，部分机构选择在高位兑现收益。板块内药明生物、药明康德、英矽智能、康龙化成等个股同步走弱，行业整体承压。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.